We should expect something new out of Landon Wed or why have the call? I would like to see some rev/earnings guidance for this year..

CYIO .....Somebody averaging down? ....Like watching a cut flower dry up and fall over ......A lottery ticket is a better buy.

....guy, I agree completely with you ....Cypro is a dead product ,,,Carnahan has been trying to sell it for many years ...Not one sale. He finds dealing with stockholders a waste of his time...He does not even talk with his IR firm ....He no longer has one. His current business is shrinking and he has no management skills to grow new business. Any investment here is dead money as it has been for all the years I followed CYIO...But maybe something will change here but the track record has been negative for the 4 years I followed it. .

When your talking about sub penny stocks,,,,Given the nature of the penny stock investor,,,A few hundred dollars worth of stock selling doesn't mean insiders are dumping....Likely it's a just one of those 'Savvy' penny players turning a 100 dollar profit or a panic sell...

Everyone who knows this stock already bought their position. We need the additional news to generate more buying ...The sell cycle for software systems can take far more time than hardware products,etc ....with this kind of company you will need patience ....2013 will be a good year...Buyers for now will sit on the bid for a bargain...

Big.....
Quture is undervalued right now IMO due to the huge amount of selling from the shell owner,,,Fong,,, Now I didn't like seeing it happen(down from the .034 area) but it did allow for buying up a large position in Quture for a fraction of the cost Pre-Fong. What a lot of penny stock traders/investors don't see here is the value and significance of the Intersystem partnership and the people who have come on board this company....These are not young wheeler-dealer types. Look at the bio's ...Paul Rudisill, Fantozzi, Candiotti, and Landon Feazell himself has an impressive bio...The product line hits an unmet need and the company must get sales but at this point the stock price is at a no risk price level and has the potential to hit .20 to .25 or more over the next year. I suspect Quture will be bought out by a bigger player after a year or two at a premium much hugher than .25..........There are a lot worse places to park your money.

NEWS ...Chevy Volt is Tops Per Consumers Reports
Chevy Volt tops Consumer Reports most-loved car survey again

Thu Nov 29, 2012 10:49am EST

Nov 29 (Reuters) - General Motors Co's Chevrolet Volt plug-in

hybrid car topped Consumer Reports' annual owner-satisfaction survey for the second straight year.Ninety-two percent of Volt owners surveyed by the influential consumer magazine said they would definitely buy the Volt again, earning the electric car the top ranking. Last year, 93 percent of respondents said they would buy the car again.

"The Volt's two-year reign at the top of our satisfaction survey points to the continuing trend of owners' enthusiasm for cars that are fuel-efficient, especially as we see more and more hybrid and electric models hitting the market," Consumer Reports' auto editor, Rik Paul, said in a statement.

The Volt, introduced in late 2010, has struggled with early soft sales, criticism from opponents of federal green-car tax credits, and a 2011 government probe of Volt battery fires that found no major problems.

Nevertheless, the Volt, which sells for just under $40,000 before a $7,500 federal tax credit, has a devoted following among those who brag about avoiding gas stations. The car can travel about 40 miles on an electric charge before the gasoline-powered engine kicks in for additional driving range.

In addition to the Volt, other fuel-efficient models that scored well in the Consumer Reports survey included the Toyota Camry Hybrid, Prius and Prius C, and the Nissan Leaf all-electric car.

On the other end of the spectrum, the redesigned Nissan Versa small car had the lowest score, with fewer than half of its owners saying they would definitely buy it again. Other low scorers included the V6-engine versions of GM's Chevy Silverado and GMC Sierra pickup trucks, and the Nissan Armada, Suzuki SX4 and Mitsubishi Outlander SUVs.

Consumer Reports said its survey received responses from owners of almost 350,000 vehicles spanning the 2010-2013 model years.

Fantozzi's working on the ROI measurement project in the Miami Hospital .....

Somebody dumped a few M shares right down to .001 a while ago .....I wish I had put in a BUY order sitting there to grab it ..The current ASK is .009

Really ....Read the full 10K
..When you can't cover the monthly costs of the business ...you got to get it somewhere ...the 10K tells you.

look at all the 'convertibles' .......and from the 10K:

"Management anticipates that any cash shortfalls will be covered by debt financing. We may pay these loans with cash, if available, or convert these loans into common stock. We may also issue private placements of stock to raise additional funding or to pay for services provided to us. Any private placement likely will rely upon exemptions from the registration requirements provided by federal and state securities laws. The purchasers and manner of issuance will be determined according to our financial needs and the available options. We also note that if we issue more shares of our common stock, our shareholders may experience dilution in the value per share of their common stock."

10Q ....
Disaster ...No Growth and more losses ,,,,,Add looming stock dilution mentioned and dispite new products this year, FVRG is in much worse shape with no end in sight. I'm out.

Is there a better fit than Rudisill for Quture???? His extensive work history could not match the needs of Quture better. Needless to say, his connections to the health industry will serve the growth of Quture for many years to come......I would expect Rudisill will hit the street running and Quture will open the eyes of the larger investment community.

There's only about 1M shares in the float .....There just is no stock available to buy under 1.00 ....There's some but any buying pressure kicks the 'ASK' well up.

Fido, I'm with you on Quture ...News with come very soon and finally a steady stream will come out and take this stock price up 10 to 20 times it's current value ....

Any cursory look into the 10Q/K tells you the problem with the stock selling in big chunks ..........BLVT was forced to pay for services in Stock ,,,since they had little access to credit and no cash on hand to cover costs. Look at the list of service providers paid in stock ...All those providers sell their stock at any price.

If you're trying to say a company with Bulova's past perforance as a company, no earnings or revenue growth,,, little access to working capital, unknown after the 11M dollar sale of assets ...is a risk? There never was a time when any investment in BLVT wasn't a risk ....I have said for years this was like buying a lottery ticket ....Which is the case for nearly all penny stocks....and many listed stocks as well.

And somebody has taken in/bought many many millions of shares over the past year ...There seems to be no limit to the amount of shares sold into the bid ....

At this Time
Anything beyond that would insider info .....Not likely anyone on this board know.

EV Sales....
..The 5 top-selling electric cars in the US
The 5 top-selling electric cars in the US
By The Associated Press | Associated Press – 14 minutes ago....Email
......

Americans have been slow to adopt electric cars. Here are the five top sellers in the U.S. this year, through August.

Car 2012 Sales
Chevrolet Volt 13,497
Toyota Prius Plug-in 6,082
Nissan Leaf 4,228
Mitsubishi i-MiEV 403
Ford Focus Electric 169

Source: Auto companies, Autodata Corp.

Old Info ....
Where's the Senate vote? ....Where's the Pres signing?

The Volt is a niche car as all EV's are. They are priced too high to actually save anyone money...If gas should climb to 6 or 8 dollars per gallon that will change.

Yes you can ...It was just done with over 2800 sold........my friend.

Good Read ....Quture's Sweet Spot!
http://www.informationweek.com/tech-center/gov-cloud/hospitals-seek-analytics-tools-in-rush-t/240005948

Note Aug Numbers ............

GM said that four vehicles -- Cruze, Spark, Sonic and Volt -- set monthly sales records in August. Cruze sold 25,975 units, Spark sold 2,630, Sonic sold 8,703 and Volt sold 2,831.

Yet Chevy Volt Aug. Numbers Set a Record @ over 2700
The old record was in Mar @ 2289 .............

Read the Volt Ref:
http://content.usatoday.com/communities/driveon/post/2012/08/big-chevy-sales-numbers-expected-today/1#.UEX3s5YjnYU

Does everyone here understand the last PR and what it means?
Take your time and read it fully............
Companies:Techs Loanstar, Inc.RELATED QUOTESSymbol Price Change
TCLN 0.0036 0.00

DAYTONA BEACH, FL--(Marketwire -08/27/12)- Quture International, Inc. (TCLN) (TCLN) and its operations subsidiary Quture, Inc. ("Quture") announce that its QualOptima product is now under contract with the University of Miami Miller School of Medicine and Jackson Memorial Hospital for a clinical trial for performance and outcomes measurement. After completing the demonstration project with InterSystems at the University, the return on investment (ROI) evaluations announced on August 8, 2012, now further include analytics focused on patient-centered, personalized medicine use of the product for hospitals to brand themselves with the same data for their patients.

As announced in June's Shareholder Letter, this additional use of clinical data from QualOptima creates sales incentives to hospitals from data generated by the product in the $700 billion hospital marketing for "branding." QualOptima will be even more on target with the urgent needs of senior management for healthcare analytics.

Quture is in the final stages of ROI evaluations from three hospital reference sites. Use of QualOptima product data for personalized medicine creates yet another financial incentive and investment opportunity for hospitals to license the product. The internal ROI evaluation parallels the Company moving to revenue-based operations as the search for its Chief Business Development Officer is nearing completion. Even at its median price point, the market opportunity for QualOptima is in excess of 1.75 billion dollars annually from hospital sales alone in the United States, and exponentially higher with either revenue model other than traditional licensing or sales to other health care market sectors. Patient-centered, personalized medicine applications create major new market sector opportunities.

In publications by Heather Woodward-Hagg at Purdue University, College of Technology, she has stated their experience with their widely accepted return on investment (ROI) methodology to calculate the business case to promote efficient, patient-centric care within a healthcare organization. In answering the question -- what is preventing the development of the business case for quality in healthcare -- she states: "In our experience, the lack of appropriate performance indicators often makes it difficult to determine performance gaps, effectively drive performance improvements and accurately measure the impact of improvement initiatives."

"Quture is intensely focused on proving and projecting the business case for QualOptima through rigorous ROI methodologies and financial projection models," said Landon Feazell, CEO of Quture International. "We are committed to the use of QualOptima to provide performance measures and analytics tools as already demonstrated in three hospitals. Health care ROI studies and formulas, and now our own ROI calculations prove the clinical logic and business case for QualOptima. Since the product captures and integrates patient-centric risk factors and outcomes measures in addition to performance measures, there is yet another huge intrinsic value for personalized medicine applications of QualOptima data. We are encouraged by the ROI evaluations to date and looking forward to this new financial revenue insight."

Quture's product demonstrations at three key hospitals have been designed to triangulate the QualOptima analytics value proposition. As the operations company moves from development to marketing and sales, the analysis of the ROI potential of the product is at completion from all three sites. Each project provides unique elements for ROI, so that the insight from each converges to attract additional reference hospitals to license QualOptima.

The clinical trial at the University of Miami Miller School of Medicine and Jackson Memorial Hospital (UoM) focused on measuring clinical performance and outcomes. Dr. Keith Candiotti designed the project to demonstrate the value of the product design to ultimately calculate unreimbursed cost relationships with compliance to evidence-based perioperative protocols. The project measures the impact of performance of evidence-based protocols on outcomes and costs. There are significant costs associated with extended stays and complications in recovery and beyond for well-established practice guidelines from professional organizations, that for the first time connect clinical quality with outcomes and costs. Electronic data capture, aggregation into a second generation database, and imposition of quality and value analytics is essential for hospitals that urgently need to move to value-based purchasing and to comply with accreditation standards. Quture is now further exploring the QualOptima database for patient-centered, personalized medicine applications with Dr. Candiotti.

At Niagara Falls Memorial Medical Center (NFMCC), Quture implemented an evidence-based optimal clinical process for prevention of catheter-acquired urinary tract infections (CAUTI) in the intensive care unit. The ROI analysis announced for completion before September is focused on payment initiatives. The clinical demonstration was selected because it is one of the hospital-acquired conditions (HAC) for which providers are no longer reimbursed and is the major patient safety initiative for 2012. Performance measurement based on a nursing-sensitive protocol augments physician performance at the University of Miami for true interdisciplinary performance measurement.

Springhill Medical Center, Springhill, LA (SMC) is focused on replacing Quture's former peer review product with QualOptima. The ROI evaluation there is based on replacing labor-intensive manual processes with electronic data capture and analytics, while integrating their peer review and performance measurement processes. Successful implementation of a license to the InterSystems product platform for QualOptima is scheduled for completion in early September. The demonstration requires completion of the product as a cloud application. This will demonstrate the market for QualOptima to small and rural medical centers such as SMC. As an established customer of the former peer review product, it was urgent to supplement peer review process with performance measurement, both for compliance with accreditation standards and to prepare for the new fee-for-value payment system.

"The recent Black Book Rankings hospital survey cited in our last press release was extraordinarily significant, stating that 84% of provider organizations without clinical analytics systems in place currently plan to acquire at least one new or additional clinical analytic tools within 12 months," said Feazell. "We have committed over six years and millions of dollars and other resources to create QualOptima. The InterSystems platform powers our product as a breakthrough application of their unparalleled technology. Senior management teams find themselves in charge, but not in control in hospitals throughout America. The survey report indicts that only 16 percent of U.S. hospitals acknowledge they currently have the clinical decision support tools to effectively manage the data needs of the accountable care evolution. Hospital boards and senior management need to prepare their organization for clinical analytics not only in the new payment system, but also for the future of improving care as patients become more involved in their care. Adding personalized medicine and wellness to the business case for QualOptima is a rapidly evolving product strategy and marketing and sales advantage. As delivery systems and payment systems are changing and patient involvement in their care increases, QualOptima empowers data-driven decisions for results-driven success.

Quture is very near completion of all that is needed by Intersytems for them to release the product line to their customer base.All the posts re Fong,etc helping knock the price down have made for a great buying opportunity....Fong was the owner of the shell only, prior to the reverse merger ...His selling has been completed ...The light volume tells you that IMO ...Everyone who understands this company already
knows all this ......I added here myself ...

Undervalued ....with the stock when @ .0002 valued this company under 300K .....Now sitting with the Euro Business and 11.2M in cash .....The debt is there yet but the cash drain of the Florida business is now gone ....

Still have the Euro Div. .....Does this become the company post sale? That division does not require any huge credit line as the Ord Div did,,,,which BLVT could not get. Waiting on Steve Gurba for comment................

They are obviously a partner ....The question of when Intersystems wants to take Quture's Software Applications to their member hospitals is the point ...The last PR gives you the answer ....Intersystems will need the ROI numbers to present to customers ....Soon to complete: from Aug 8th,,


Quture International, Inc. (OTCQB: TCLN) (PINKSHEETS: TCLN) and its operations subsidiary Quture, Inc. ("Quture") announce that its QualOptima product demonstrations are on target with hospital IT leaders' demands and the urgent needs of senior management for healthcare analytics. Quture is in the final stages of return on investment (ROI) evaluations from three hospital reference sites as the Company moves to revenue-based operations and nears completion of the search for its Chief Business Development Officer. Even at its median price point, the market opportunity for QualOptima is in excess of 1.75 billion dollars annually in the United States alone, and exponentially higher with revenue models other than traditional licensing.

Partner List ...
The Intersystem website will get updated with Quture soon IMO ...
They have been working together through 2012......

This PR from Mar ,,,

Quture, Inc. Senior Leaders Participate at InterSystems Global Summit
PrintAlert
Techs Loanstar, Inc." (QB) (USOTC:TCLN)

Techs Loanstar, Inc. (OTCQB: TCLN) (PINKSHEETS: TCLN), d/b/a Quture, Inc., the future in global health and healthcare quality, patient safety and value, announced today that the company's senior management team is in attendance at the 2012 InterSystems Global Summit in Orlando. The Summit is the annual InterSystems event for participants from 32 countries designed for the InterSystems community to reach peak performance. As an Application Partner of InterSystems, Quture is participating in the Partner Pavilion and is making presentations to the InterSystems sales teams at the Partner Awareness session. While Quture leadership is participating in the Developers Conference and the Leadership Conference, the Company's CEO, Richard Fantozzi, M.D., is speaking on a panel at the Healthcare Leadership Conference on performance measurement as it advances peer review and proctoring in the core competence of Quture and its products and services.

This PR from April,,,,

Quture/TCLN Announces Successful Migration of Peer Review Product Onto InterSystems Platform

Techs Loanstar, Inc." (QB) (USOTC:TCLN)
Quture International, Inc. (OTCQB: TCLN) (PINKSHEETS: TCLN) and its operations subsidiary Quture, Inc. ("Quture") announce migration of the Company's existing software product to perform peer review of clinical performance in hospitals from Microsoft to the InterSystems platform. Quture previewed this first transition to its new QualOptima System at the Partner Pavilion of the InterSystems Global Summit. The peer review application is an asset from Quture's recent merger and is being readied for commercial sales of this existing product on the more powerful InterSystems technology. The inherent limitations of peer review for hospitals will be overcome through the electronic performance measurement technology proven at Demonstration Sites.
The new peer review application in QualOptima will continue to advance peer review from anecdotal, unstructured and subjective to electronic, structured, and evidenced-based explicit analytics. The product will be introduced into a market for the peer review application, next to be enhanced with proctoring to complete the application, with a market potential estimated in excess of $500,000,000 in the United States alone.
"The prospects for Quture to change the peer review processes to enhance clinical performance and achieve optimal clinical outcomes was one of my primary motivations to join the Company," said Richard Fantozzi, M.D., CEO and Co-Chairman of Quture. "During my term with the medical board in California, we dealt frequently with peer review issues and had the opportunity to see the development of the Lumetra Report. When the results of that study were published, they confirmed my concern that peer review is an essential process, but is often poorly performed and under reported. We believe that there are other health communities that see the essential value of using the performance enhancement tool."
"Quture is poised to commercially market a truly revolutionary product to enhance performance measurement and to achieve what is possible to improve both healthcare delivery and payment systems internationally," he added.
The QualOptima System peer review application is the first commercial product release of Quture, soon to be enhanced with electronic proctoring and performance measurement following the Demonstration Projects at the University of Miami, Miller School of Medicine, Jackson Memorial Hospital, under the leadership of Keith Candiotti, M.D., and at Niagara Falls Memorial Medical Center, under the leadership of Judith Daugherty, R.N., Ph.D.
"My colleagues and I have worked for over 35 years and I have invested over $3 million to accomplish this new peer review application," said Landon Feazell, Chairman & CEO of Quture International, Inc. "It is truly remarkable that years of development of intellectual property and clinical content are now converging on a remarkable technology platform to derive clinical knowledge solutions. We can now replace outdated manual review yielding only anecdotal subjective data with limited impact on health care processes. Dr. Janice Ophoven, Chief Medical Officer of Quture and her team have worked with us throughout the years to develop these assets to transition to evidence-based, structured implicit review. I am proud and excited to finally begin to announce our accomplishments with this new technology and science of healthcare quality and patient safety."

You have been had ....The CEO does not like or understand shareholders. He, Carnahan, has no CEO skills whatsoever. He has not added a new contract in 3 years ....Old contracts will likely run out. Does this sound like a good investment? ...I sold out but I occasionally look back.

chance ,,,,,I like the continual additions to the business CCGI is getting done. The question is how soon can they monitize the charging base. When will there be enough EV/Hybrid cars out there to generate revenue. The stock float is small at 15M shrs and tightly held apparently as there is little selling. I own some but what will kick this stock up? ...There is a listing push to the NASD and that will require buying in this stock to meet the listing requirement .....Long term this company looks to be the leader in the space and EV/Hybrids are selling very well and may really jump as gas prices move up.Patience...........

You do understand this is a development company moving into the sales phase right? That was a 10K release, meaning it's OLD news from last year(fiscal). All recent accomplishments, as well as Fong's stock position(from the old shell company) are not part of that 10K. With Quture you focus on what this company is getting done over the weeks and months ...contracts, customers, products, etc ... You will need patience here ....

Where this Industry is Going .....
GM CEO Akerson Says To Expect All-Electric Car With 200 Mile Range
0 0 0 GM CEO Dan Akerson announced that subsidiary Envia Systems has made progress on the development of a battery that could allow an electric car to go up to 200 mils on a single charge. The company believes that such an advance could happen within the next four years, and become a game changer in the electric car business.

While still in its relative infancy, competition is fierce between electric cars, such as Chevrolet’s Volt and the Nissan Volt. Toyota (TM) has begun to manufacture a plug in hybrid based on its popular Prius model, but the car only goes 11 miles in all electric mode. Tesla Motors does have a model that can go 300 miles on a single charge, but the batteries are large, heavy, and expensive

News on Intersystems
Press Releases


InterSystems Rises to 30th Place on
Healthcare Informatics 100 List
Demand for InterSystems' Connected Care Technologies
Propels High Placement on Prestigious Annual Ranking
of Healthcare IT Companies

--------------------------------------------------------------------------------
Cambridge MA — August 9, 2012—InterSystems Corporation, a global leader in software for connected care, today announced it has been ranked the 30th largest healthcare IT provider by Healthcare Informatics, a leading healthcare industry publication. The 2012 Healthcare Informatics 100 ranks the top companies based on revenues derived from healthcare IT products and services earned in the United States in 2011.

InterSystems' revenue in 2011 from healthcare-related clients grew nearly 16.5 percent over the prior year, propelling the company from 34th to 30th place. It is the 14th consecutive year that InterSystems has appeared on this ranking of top healthcare IT companies.

InterSystems products and advanced technologies for connected care include InterSystems HealthShare™, a strategic healthcare informatics platform that enables hospitals, integrated delivery networks, and regional and national health information exchanges to capture, share, understand, and act on data to optimize care and improve organizational results.InterSystems CACHÉ® is the world's most widely used database system in clinical applications. InterSystems Ensemble® is a platform for rapid integration and the development of connectable applications.

"InterSystems supplies innovative data management, integration, and analytics software to many of the healthcare application vendors listed on the Healthcare Informatics 100, such as Epic Systems Corporation and GE Healthcare, as well as directly to many of America's best known hospitals," said Paul Grabscheid, InterSystems Vice President of Strategic Planning. "We are seeing strong growth for our HealthShare strategic informatics platform, which enables healthcare professionals to leverage their existing systems, and the vast amounts of untapped patient data within them, to drive informed action and improve patient outcomes."

The 2012 Healthcare Informatics 100 was published in the June 2012 issue of Healthcare Informatics magazine. For a complete list of the Healthcare Informatics 100 winners, visit http://www.healthcare-informatics.com/hci100/2012-healthcare-informatics-100-ranking.

About InterSystems

InterSystems Corporation is a global leader in software for connected care, with headquarters in Cambridge, Massachusetts, and offices in 25 countries. InterSystems CACHÉ® is the world's most widely used database system in clinical applications. InterSystems Ensemble® is a platform for rapid integration and the development of connectable applications. InterSystems HealthShare™ is a strategic healthcare informatics platform for information exchange and analytics within a hospital network, and across a community, region or nation. HealthShare leverages InterSystems iKnow and DeepSee technologies to unlock all patient information, including unstructured data, and to enable real-time analysis.

InterSystems' products are used by thousands of hospitals and laboratories worldwide, including all of the top ten hospitals on the Honor Roll of America's Best Hospitals as rated by U.S. News and World Report.

For more information, visit InterSystems.com, www.youtube.com/InterSystemsCorp, www.facebook.com/InterSystems, or @InterSystems on Twitter.

####

Editorial Contacts

Catherine Marenghi
InterSystems
(617) 225-3179
pr@intersystems.com

500K @ ask now .....Some 255M on the bid at @ .0002 ,,,,,Will be tough to get a fill at the bid price .........What will a cashflow positive or profitable BLVT be valued at? ....We shall see per the update

In the heading is tells you 'Alphabetical order' ...

Not a problem at Scottrade ....

News on Quture Partner, Intersystems
InterSystems Recognized by SD Times for Innovation and Leadership in Database Technologies
InterSystems Included in Prestigious SD Times 100 Ranking for Fourth Consecutive Year

updated 7/30/2012 9:03:00 AM ET 2012-07-30T13:03:00
Print Font: +-CAMBRIDGE, MA — InterSystems Corporation, a global provider of advanced technologies for breakthrough applications, today announced it was named one of the software industry's top 100 innovators by SD Times. This is the fourth consecutive year that the editors of SD Times have recognized InterSystems in the annual software industry ranking.

The Editorial Board of BZ Media's SD Times chose the 100 leading companies based on a careful evaluation of achievements in the previous calendar year. "We take into consideration each company's offerings, reputation, and 'buzz' -- the attention and conversation we've heard around the company and its products and technologies. Many factors point to leadership within the software development industry," the SD Times editors stated in the June 2012 issue.

InterSystems received its honor in the "Database and Data Tools" category, which spotlights the companies that "just plain get it when it comes to databases, and how to connect them to ever-expanding, ever-changing endpoints," according to SD Times.

"This recognition is particularly gratifying, coming from the independent perspective of SD Times' editorial leadership," said Paul Grabscheid, InterSystems Vice President of Strategic Planning. "Our vision is to enable software developers to create breakthrough applications that don't just automate processes, but dramatically enhance how users work."

About the SD Times 100

SD Times (www.sdtimes.com) is the newspaper of record for the software development industry, reaching more than 60,000 subscribers in 131 countries. The annual SD Times 100 list, selected by the editors of SD Times, "recognizes companies, non-commercial organizations, open source projects, and other initiatives for their innovation and leadership." For a complete list of the 2012 SD Times 100 winners, visit http://www.sdtimes.com/content/article.aspx?ArticleID=36641.

About InterSystems

InterSystems Corporation is a global software leader with headquarters in Cambridge, Massachusetts, and offices in 25 countries. InterSystems provides advanced technologies for breakthrough applications. InterSystems CACHÉ® is an extremely fast and massively scalable database system. InterSystems Ensemble® is a platform for rapid integration and the development of connectable applications. InterSystems DeepSee™ is a technology that makes it possible to embed real-time active analytics capabilities in transactional applications.

erb.. Do you know what a 'reverse merger' is? ......Into a bankrupt shell ....Fong was part of the original TCLN ......Fong has nothing to do with Quture ....Everyone here knows this .....The stock symbol, TCLN, is the only connection to the Fong era.